Proposed LCDs Will Restrict Glaucoma Care for Your Patients
Take Action Now!

Protect your Right to Medical Decision Making

A multijurisdictional Local Coverage Decision (LCD) has been proposed for “Anterior Segment Intraocular Nonbiodegradable Drug-eluting System”, i.e., iDose® TR. The Medicare Administrative Contractors (MACs) included in the proposed LCD include Cigna Government Services (CGS), National Government Services (NGS) now WellPoint Federal, Noridian, Palmetto and Wisconsin Physician Services (WPS). A 45-day comment period is currently open through July 4, 2026 for all five MACs.

Now is the time for Medicare providers to advocate for coverage criteria of iDose® TR so that patients can access this minimally-invasive, long duration glaucoma treatment.

Your comment must be submitted by July 4, 2026, to be considered for this proposed LCD.

iDose® TR is a first-of-its-kind, long-duration, anchored intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications. iDose® TR is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Proposed LCD limitations include:

  • Requiring failure of at least 2 topical medications AND SLT prior to iDose TR.
  • Restricting iDose TR in conjunction with other glaucoma procedures
  • Additional requirements beyond approved labeling prior to retreating with iDose TR

"*" indicates required fields

Step 1 of 2

This field is for validation purposes and should be left unchanged.

Now is the time to act!

The 45-day comment period closes on .

Select your state in the form to submit your comment to the appropriate Medicare Contractor.

Your comment must be submitted by to be considered for this proposed LCD.

The proposed LCD is currently in draft form and has not been implemented. Coverage for iDose TR remains unchanged until the LCD review and adoption process is completed.

Important Safety Information

iDose TR is gently placed directly inside your eye by your eye doctor.

You should not have iDose TR if you have an infection or suspected infection in your eye or the area surrounding your eye, have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally as this can cause vision problems, have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant), are allergic to any of its ingredients, and/or have narrow angles (the iris and the cornea are too close together).

The most common side effect of iDose TR was increased eye pressure. Other common side effects were inflammation of the iris, dry eye, a loss of part of the usual field of vision, eye pain, eye redness and reduced clearness of vision.

If you have additional questions, please contact your doctor. For full Prescribing Information click here.

Approved Uses

iDose TR (travoprost intracameral implant) is a prescription medicine and drug delivery system for the eye approved to lower eye pressure in patients with open-angle glaucoma or high eye pressure (ocular hypertension).

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.